LivaNova PLC (NASDAQ:LIVN) Position Boosted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 163.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 546,387 shares of the company's stock after acquiring an additional 339,139 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 1.01% of LivaNova worth $25,303,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC raised its position in LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after purchasing an additional 1,441 shares during the period. Central Pacific Bank Trust Division grew its stake in shares of LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after buying an additional 720 shares in the last quarter. Vestcor Inc purchased a new stake in LivaNova during the fourth quarter worth about $204,000. Finally, Optimize Financial Inc purchased a new stake in LivaNova during the 4th quarter worth approximately $208,000. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LIVN. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. Barclays lowered their target price on LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a report on Friday, March 7th. Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Mizuho lowered their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, LivaNova has a consensus rating of "Buy" and an average price target of $59.33.

LivaNova Price Performance

LIVN stock traded up $0.60 on Thursday, hitting $44.10. 451,139 shares of the company's stock traded hands, compared to its average volume of 629,927. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 104.87 and a beta of 0.84. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $63.57. The stock has a fifty day moving average of $37.79 and a 200-day moving average of $45.33. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.